Hepion Pharmaceuticals, Inc.

0.0720+0.01 (+10.8%)

Oct 29, 4:00:00 PM EDT · OTC Markets OTCQB · HEPA · USD

Upcoming Earnings

Report date

≈ -

Key Stats

Market Cap

836.66K

P/E (TTM)

Basic EPS (TTM)

-45.85

Dividend Yield

Recent Filings

10-Q

Q2 FY2025 results

8/14/25Aug 14, 2025

Hepion Pharmaceuticals narrowed its Q2 operating loss to $1.7 million from $8.5 million a year earlier, thanks to slashed R&D spending after winding down its liver drug trial, though a $0.4 million asset impairment hit from a new diagnostics license deal tempered gains. Net loss eased to $1.0 million, or $0.09 per share, versus $3.9 million, or $34.00 per share, with the EPS swing reflecting a 98-fold jump in diluted shares to 11.3 million from warrant conversions—no anti-dilution flagged. Cash climbed to $2.9 million on $9.0 million from a January equity raise, which cleared a $2.9 million note, leaving $0.4 million in short-term debt for insurance; free cash flow not disclosed in the 10-Q. The May license for EU-eligible celiac, respiratory, and H. pylori tests cost $0.8 million total but got fully impaired over dim near-term cash flow prospects. Warrants pose a key risk, their fair value swings hammering earnings.

8-K

CFO resigns for personal reasons

6/30/25Jun 30, 2025

Hepion Pharmaceuticals' CFO and director John Brancaccio resigned for personal reasons, effective June 30, 2025, following the announcement on June 25. The departure leaves a gap in financial leadership at the Nasdaq-listed biotech. No successor named yet.

8-K

Shareholders reject reverse split

6/12/25Jun 12, 2025

Hepion Pharmaceuticals held its 2025 Annual Meeting on June 12, where shareholders elected John P. Brancaccio, Timothy Block, Kaouthar Lbiati, and Michael Purcell to the board amid significant withhold votes. They ratified Grassi & Co. as auditors for 2025, but rejected a proposed reverse stock split ranging from 1-for-5 to 1-for-20. Say-on-pay compensation drew majority opposition. The split denial signals investor pushback on dilution tactics.

8-K

Interim CEO appointment announced

6/9/25Jun 9, 2025

Hepion Pharmaceuticals appointed board director Dr. Kaouthar Lbiati as interim CEO effective June 16, 2025, following board approval on June 3. She'll serve a three-month term at $350,000 annual base salary, with $50,000 deferred until a $3 million equity raise or her exit. A 35% performance bonus ties to agreed milestones. This shift stabilizes leadership amid biotech pressures.

8-K

Hepion divests Rencofilstat assets

5/30/25May 30, 2025

Hepion Pharmaceuticals sold its Rencofilstat patent assets, knowhow, clinical data, and drug product to Panetta Partners for a nominal amount on May 26, 2025. Stockholders receive contingent value rights for up to $4.5 million in milestone payments: $500,000 on FDA approval, $1 million on $350 million net sales, and $3 million on $750 million net sales. This divestiture streamlines Hepion's focus, yet ties future value to Rencofilstat's distant success. Payments hinge on regulatory and commercial hurdles.

About

Hepion Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatment for hepatocellular carcinoma (HCC) and other chronic liver diseases in the United States. It develops Rencofilstat, a therapeutic drug candidate that binds and inhibits the function of a specific class of isomerase enzymes called cyclophilins that regulates protein folding, as well as preclinical experiments of Rencofilstat reflects decreased liver fibrosis; liver inflammation; liver tumor burden; and titers of HBV, HCV, HDV, and HIV-1. The company was formerly known as ContraVir Pharmaceuticals, Inc. and changed its name to Hepion Pharmaceuticals, Inc. in July 2019. Hepion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Morristown, New Jersey.

CEO

Dr. Kaouthar Lbiati M.D.

IPO

2/10/2014

Website

https://hepionpharma.com

Sector

Healthcare

Industry

Biotechnology